Literature DB >> 28756085

Differentiation of Intrahepatic Cholangiocellular Carcinoma from Hepatocellular Carcinoma in the Cirrhotic Liver Using Contrast-enhanced MR Imaging.

Georg J Wengert1, Pascal A T Baltzer2, Hubert Bickel2, Patrick Thurner2, Julia Breitenseher2, Mathias Lazar2, Matthias Pones2, Markus Peck-Radosavljevic3, Florian Hucke3, Ahmed Ba-Ssalamah2.   

Abstract

RATIONALE AND
OBJECTIVES: This study aimed to investigate the potential of contrast-enhanced magnetic resonance imaging features to differentiate between mass-forming intrahepatic cholangiocellular carcinoma (ICC) and hepatocellular carcinoma (HCC) in cirrhotic livers.
MATERIALS AND METHODS: This study, performed between 2001 and 2013, included 64 baseline magnetic resonance imaging examinations with pathohistologically proven liver cirrhosis, presenting with either ICC (n = 32) or HCC (n = 32) tumors. To distinguish ICC form HCC tumors, 20 qualitative single-lesion descriptors were evaluated by two readers, in consensus, and statistically classified using the chi-square automatic interaction detection (CHAID) methodology. Diagnostic performance was assessed by a receiver operating characteristic analysis.
RESULTS: The CHAID algorithm identified three independent categorical lesion descriptors, including (1) liver capsular retraction; (2) progressive or persistent enhancement pattern or wash-out on the T1-weighted delayed phase; and (3) signal intensity appearance on T2-weighted images that could help to reliably differentiate ICC from HCC, which resulted in an AUC of 0.807, and a sensitivity and specificity of 68.8 and 90.6 (95% confidence interval 75.0-98.0), respectively.
CONCLUSIONS: The proposed CHAID algorithm provides a simple and robust step-by-step classification tool for a reliable and solid differentiation between ICC and HCC tumors in cirrhotic livers.
Copyright © 2017 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Liver; MRI; hepatocellular carcinoma; liver cirrhosis; mass-forming intrahepatic cholangiocellular carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28756085     DOI: 10.1016/j.acra.2017.06.005

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  8 in total

1.  Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018.

Authors:  Xianlun Zou; Yan Luo; John N Morelli; Xuemei Hu; Yaqi Shen; Daoyu Hu
Journal:  Abdom Radiol (NY)       Date:  2021-03-03

2.  Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

Authors:  Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu Yamamoto
Journal:  Liver Cancer       Date:  2022-02-23       Impact factor: 12.430

3.  Value of Intravoxel Incoherent Motion (IVIM) Imaging for Differentiation between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.

Authors:  Jinhua Wang; Zhongxian Yang; Min Luo; Cui Xu; Mu Du; Yubao Liu
Journal:  Contrast Media Mol Imaging       Date:  2022-05-10       Impact factor: 3.009

4.  Automated machine learning for differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma on multiphasic MRI.

Authors:  Rong Hu; Huizhou Li; Hannah Horng; Nicole M Thomasian; Zhicheng Jiao; Chengzhang Zhu; Beiji Zou; Harrison X Bai
Journal:  Sci Rep       Date:  2022-05-13       Impact factor: 4.996

5.  Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.

Authors:  Tyler J Fraum; Roberto Cannella; Daniel R Ludwig; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Eur Radiol       Date:  2019-10-25       Impact factor: 5.315

6.  Diagnosis of Liver Neoplasms by Computational and Statistical Image Analysis.

Authors:  Rong Xia; Amir M Boroujeni; Stephanie Shea; Yongsheng Pan; Raag Agrawal; Elhem Yousefi; M Isabel Fiel; M A Haseeb; Raavi Gupta
Journal:  Gastroenterology Res       Date:  2019-11-21

7.  Liver Imaging and Data System (LI-RADS) Version 2018 and Other Imaging Features in Intrahepatic Cholangiocarcinoma in Chinese Adults with vs. without Chronic Hepatitis B Viral Infection.

Authors:  Ying-Ying Liang; Shuo Shao; Sichi Kuang; Jingbiao Chen; Jing Zhou; Bingjun He; Linqi Zhang; Yao Zhang; Kathryn J Fowler; Jin Wang
Journal:  Can J Gastroenterol Hepatol       Date:  2021-03-04

8.  Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: A meta-analysis.

Authors:  Xujian Huang; Jialin Yang; Jingdong Li; Yongfu Xiong
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.